Phio Pharmaceuticals Stock
Phio Pharmaceuticals Corp.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Robert L. Bitterman
- Employees
- 6
- Market cap
- $10 M
- IPO
- 10/05/2012
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL…
Phio Pharmaceuticals stock: price history
1D
-5.9%
1W
-11.0%
1M
-12.8%
6M
-32.5%
YTD
-17.0%
1Y
-58.9%
2Y
-73.2%
5Y
-99.5%
10Y
-100.0%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~67% weaker price swings than usual
Ask the agents about Phio Pharmaceuticals
Analyst assessment of Phio Pharmaceuticals
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 26/08/2026
Phio Pharmaceuticals stock metrics
P/E
-0.65
P/B
0.8
EV/EBITDA
0.22
RETURN ON EQUITY
-32.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.9%
FLOAT SHARES
11,256,302
AVG. DAILY VOLUME (30D)
110,030
Insider transactions (SEC)
Plott Ronald Todd
Plott Ronald Todd
Bitterman Robert J
Plott Ronald Todd
Carson Lisa Cabott
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Phio Pharmaceuticals stock
What does Phio Pharmaceuticals do?
Phio Pharmaceuticals Corp. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Robert L. Bitterman, the company employs around 6 people.
The IPO was on 10/05/2012; the stock trades on NASDAQ under the ticker PHIO.
What do analysts say about Phio Pharmaceuticals stock?
2 analysts rate the stock, the consensus is Buy (as of 26/08/2026).
This is an external assessment, not a statement by Market Jury.
When does Phio Pharmaceuticals report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -67% stronger than usual.
Does Phio Pharmaceuticals pay a dividend?
No, Phio Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Phio Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Phio Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Phio Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.